Healthcare professionals can find information about approved indications for LIBTAYO (cemiplimab-rwlc) along with treatment guidelines and resources. Review Important Safety Information and full Prescribing Information.

LIBTAYO is indicated for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Review Important Safety Information and full Prescribing Information.

Advanced CSCC LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.1

LIBTAYO is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.

LIBTAYO is indicated as a 1L treatment in certain advanced NSCLC as a monotherapy with PD-L1 expression ≥ 50% and no EGFR, ALK, ROS1, and combination therapy with platinum-based chemotherapy with no EGFR, ALK, ROS1. Review Important Safety Information and full Prescribing Information.

View Study 1423 and Study 1540 trial designs used to evaluate the efficacy and safety of LIBTAYO in metastatic or locally advanced CSCC in patients who were not candidates for curative surgery or curative radiation. Review Important Safety Information and …

Learn how LIBTAYO Surround® may help eligible patients access LIBTAYO. Review Important Safety Information and full Prescribing Information.

Please contact LIBTAYO Surround or your local Reimbursement Manager. For more information or if you have questions, contact your Reimbursement Manager or call LIBTAYO Surround at 1.877.LIBTAYO (1.877.542.8296) Option 1, Monday–Friday, 8 AM–8 PM Eastern time.

For any questions or concerns, or to report side effects with a Regeneron product for patients enrolled in LIBTAYO Surround, please contact LIBTAYO Surround at 1.877.LIBTAYO (1.877.542.8296) Option 1, Monday–Friday, 8 AM–8 PM Eastern time.

Cemiplimab-rwlc (LIBTAYO ®) is recommended by national guidelines for advanced BCC 9 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Basal Cell Skin Cancer V.3.2024 include cemiplimab-rwlc (LIBTAYO ®) as a recommended systemic therapy option for appropriate patients with advanced BCC 9¶